Status:
COMPLETED
A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
In this study, a 10 mg dose of CP-690,550 will be given to study subjects on two separate occasions by two different routes of administration: One time by mouth in tablet form and one time by vein (in...
Detailed Description
To estimate the absolute bioavailability of a 10 mg oral dose of tasocitinib (CP-690,550) compared to a 10 mg intravenous dose of tasocitinib (CP-690,550) in healthy subjects.
Eligibility Criteria
Inclusion
- Healthy male and/or female (non childbearing potential)
- Subjects between the ages of 21 and 55 years, inclusive
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs)
- No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
Exclusion
- Evidence or history of any clinically significant illness, medical condition, or disease.
- 2\. Evidence or history of any clinically significant infections within the past 3 months.
- 3\. Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01143805
Start Date
July 1 2010
End Date
August 1 2010
Last Update
August 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Singapore, Singapore, 188770